Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
Dr Maximilian F Konig, Alfred Hj Kim, Marc H Scheetz, Elizabeth R Graef, Jean W Liew, Julia Simard, Pedro M Machado, Milena Gianfrancesco, Jinoos Yazdany, Daman Langguth, Dr Philip C Robinson
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217690
Disclaimer The views expressed here are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance, and do not necessarily represent the views of the American College of Rheumatology, the European League Against Rheumatism, or any other organisation.
References
Ahj, Sparks, Liew, A rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19, Ann Intern Med
Arnold, Buckner, Hydroxychloroquine for treatment of SARS-CoV-2 infection? improving our confidence in a model-based approach to dose selection, Clin Transl Sci,
doi:10.1111/cts.12797Barnard, Day, Bailey, Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice, Antivir Chem Chemother,
doi:10.1177/095632020601700505Chen, Hu, Zhang, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Epidemiology
Chorin, Dai, Shulman, The QT interval in patients with SARS-CoV-2 infection treated with Hydroxychloroquine/Azithromycin, Cardiovascular Medicine
Dyall, Coleman, Hart, Repurposing of clinically developed drugs for treatment of middle East respiratory syndrome coronavirus infection, Antimicrob Agents Chemother,
doi:10.1128/AAC.03036-14Dyall, Gross, Kindrachuk, Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies, Drugs,
doi:10.1007/s40265-017-0830-1Gianfrancesco, Hyrich, Gossec, Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries, Lancet Rheumatol,
doi:10.1016/S2665-9913(20)30095-3Lane, Weaver, Kostka, Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study, Rheumatology
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-020-0156-0Mathian, Mahevas, Rohmer, Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine, Ann Rheumat Dis
Monti, Montecucco, Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit, Ann Rheum Dis
Petri, Elkhalifa, Li, Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy, Arthritis Rheumatol,
doi:10.1002/art.41121Rayner, Bulik, Kamal, Pharmacokinetic-Pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies, Antimicrob Agents Chemother,
doi:10.1128/AAC.02440-12Roden, Harrington, Poppas, Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment, J Am Coll Cardiol,
doi:10.1016/j.jacc.2020.04.016Tang, Cao, Han, Hydroxychloroquine in patients with COVID-19: an openlabel, randomized, controlled trial, Infectious Diseases,
doi:10.1101/2020.04.10.20060558Trump, Vice, Pence, Members of the Coronavirus Task Force in Press Briefing
Tuntland, Ethell, Kosaka, Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of biomedical research, Front Pharmacol,
doi:10.3389/fphar.2014.00174Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237
